<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FUROSEMIDE 1%- furosemide syrup </strong><br>FIRST PRIORITY INCORPORATED<br></p></div>
<h1>  Furosemide Syrup 1 % (10 mg/mL)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section" data-sectionCode="50744-2">
<a name="Le9f8dc0d-3173-4603-8a8f-2c4c50c95771"></a><a name="section-1"></a><p></p>
<p class="First"><br><span class="Bold">FOR USE IN DOGS ONLY</span></p>
<p><span class="Bold">A diuretic-saluretic for prompt relief of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="Lccc26df0-f625-4a12-bb31-56ee5fd75052"></a><a name="section-2"></a><p></p>
<p class="First"><span class="Bold">Caution:</span> Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="L856d9463-487d-4cc6-9cc6-43f8b3abfdfe"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Furosemide Syrup 1% is a chemically distinct diuretic and saluretic pharmacodynamically characterized by the following:</p>
<p></p>
<ol>
<li>A high degree of efficacy, low-inherent toxicity and a high therapeutic index.</li>
<li>A rapid onset of action of comparatively short duration. <span class="Sup">1,2</span>
</li>
<li>A pharmacologic action in the functional area of the nephron, i.e., proximal and distal tubules and the ascending limb of the loop Henle. <span class="Sup">2,4</span>
</li>
<li>A dose-response relationship and a ratio of minimum to maximum effective dose range greater than ten fold. <span class="Sup">1,2</span>
</li>
<li>It is administered orally. It is readily absorbed from the intestinal tract and well tolerated.</li>
</ol>
<p>The CAS Registry Number is: 54-31-9.</p>
<p>This product contains alcohol 11.5% USP as a preservative, and FD&amp;C Yellow #6 and D&amp;C Yellow #10 as color additives.</p>
<p>Furosemide Syrup 1%, a diuretic, is an anthranilic acid derivative with the following structural formula:</p>
<p><img alt="image of Furosemide Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9ca6640e-dbfb-4bcd-bf3e-c8c68b7d41a1&amp;name=Furosemide%20Structure.jpg"></p>
<p></p>
<p>Generic name: Furosemide (except in United Kingdom-frusemide). Chemical name: 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid.</p>
</div>
<div class="Section" data-sectionCode="43679-0">
<a name="Lda12faf6-8549-4a78-a199-4a2278495ab2"></a><a name="section-4"></a><p></p>
<h1>ACTIONS</h1>
<p class="First">The therapeutic efficacy of Furosemide Syrup 1 % is from the activity of the intact and unaltered molecule throughout the nephron, inhibiting the reabsorption of sodium not only in the proximal and distal tubule, but also in the ascending limb of the loop of Henle. The prompt onset of action is a result of the drug's rapid absorption and a poor lipid solubility. The low lipid solubility and a rapid renal excretion minimizes the possibility of lipid accumulation in tissues and organs or of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>. Furosemide Syrup 1 % has no inhibitory effect on carbonic anhydrase or aldosterone activity in the distal tubule. The drug possesses diuretic activity in the presence of either <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> or <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>. <span class="Sup">1-7</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="L55378110-e8fe-4314-9360-2f6c6d5b6fcd"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS<br>DOG</h1>
<p class="First">Furosemide Syrup 1% is an effective diuretic possessing a wide therapeutic range. Pharmacologically it promotes the rapid removal of abnormally retained extracellular fluids. The rationale for the efficacious use of diuretic therapy is determined by the clinical pathology producing the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>Furosemide Syrup 1% is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>) associated with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac insufficiency</span> and acute noninflammatory tissue <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. The continued USB of heart stimulants, such as digitalis or its glycosides, is indicated in cases of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> involving <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="L46d08370-33d4-4583-aa83-557130ebfcbc"></a><a name="section-6"></a><p></p>
<h1>  CONTRAINDICATIONS-PRECAUTIONS
</h1>
<p class="First">Furosemide Syrup 1% is a highly effective diuretic-saluretic which if given in excessive amounts may result in <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>. Therefore, the dosage and schedule may have to be adjusted to the patients' needs. The animal should be observed for early signs of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, and corrective measures administered. Early signs of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> are: <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Increased thirst</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Special attention should be given to potassium levels.</p>
<p>Furosemide Syrup 1% may lower serum calcium levels and cause <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> in rare cases of animals having an existing hypocalcemic tendency. <span class="Sup">10-14</span></p>
<p>Although <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus is a rarely reported disease in animals, active or <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may on rare occasions be exacerbated by Furosemide Syrup 1%. While it has not been reported in animals, the use of high doses of salicylates, as in rheumatic diseases, in conjunction with Furosemide Syrup 1% may result in salicylate toxicity because of competition for renal excretory sites. Electrolyte balance should be monitored prior to surgery in patients receiving Furosemide Syrup 1%. Imbalances must be corrected by administration of suitable fluid therapy.</p>
<p>Furosemide Syrup 1% is contraindicated in <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>. Therapy should be discontinued in cases of progressive <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> if increasing <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occur during the treatment. Sudden alterations of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> in an animal with cirrhosis may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>; therefore, observation during period of therapy is necessary. In <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> and in states of <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, therapy should not be instituted until the basic condition is improved or corrected. Potassium supplementation may be necessary in cases routinely treated with potassium depleting steroids.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Leca6d366-de2b-4b47-a323-370f8b5d8275"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Furosemide Syrup 1% is a highly effective diuretic and, as with any diuretic, if given in excessive amounts may lead to excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> that could result in <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and reduction of plasma volume, enhancing the risk of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. Therefore, the animal should be observed for early signs of fluid depletion with <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, and corrective measures administered. Excessive loss of potassium in patients receiving digitalis or its glycosides may precipitate <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. Caution should be exercised in animals administered potassium-depleting steroids.</p>
<p>It is important to correct <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">potassium deficiency</span> with dietary supplementation. Caution should be exercised in prescribing enteric-coated potassium tablets.</p>
<p>There have been several reports in human literature, published and unpublished, concerning nonspecific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of enteric-coated thiazides with potassium salts. These lesions may occur with enteric-coated potassium tablets alone or when they are used with non-enteric-coated thiazides, or certain other oral diuretics. These small-bowel lesions may have caused obstruction, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and perforation. Surgery was frequently required, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred. Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously. Therefore, coated potassium-containing formulations should be administered only when indicated, and should be discontinued immediately if <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, distension, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> occurs.  Human patients with known sulfonamide sensitivity may show <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to Furosemide Syrup 1 %; however, these reactions have not been reported in animals.</p>
<p>Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine. Caution should be exercised in administering curare or its derivatives to patients undergoing therapy with Furosemide Syrup 1% and it is advisable to discontinue Furosemide Syrup 1% for one day prior to any elective surgery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="La6e81f79-d76c-4335-a170-f4c308f5a53a"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual dose of Furosemide Syrup 1 % is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg). Administer once or twice daily at 6- to 8-hour intervals orally. A prompt <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> usually ensues from the initial treatment. <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Diuresis</span> may be initiated by the parenteral administration of furosemide injection and then maintained by oral administration.</p>
<p>The dosage should be adjusted to the individual's response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 1 mg/lb body weight. The established effective dose should be administered once or twice daily. The daily schedule of administration can be timed to control the period of micturition of the convenience of the client or veterinarian. Mobilization of the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may be most efficiently and safely accomplished by utilizing an intermittent daily dosage schedule, i.e., every other day or 2 to 4 consecutive days weekly.</p>
<p>Diuretic therapy should be discontinued after reduction of the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, or maintained after determining a carefully programmed dosage schedule to prevent recurrence of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. For long-term treatment, the dose can generally be lowered after the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> has once been reduced.</p>
<p>Re-examination and consultations with client will enhance the establishment of a satisfactorily programmed dosage schedule. Clinical examination and serum BUN, CO<span class="Sup">2</span> and electrolyte determinations should be performed during the early period of therapy and periodically thereafter, especially in refractory cases. Abnormalities should be corrected or the drug temporarily withdrawn.</p>
<p><span class="Bold">DOSAGE</span></p>
<p><span class="Bold">ORAL:</span></p>
<p><span class="Bold">DOG-Syrup 1 %</span></p>
<p>One (1) to two (2) mL (10 to 20 mg furosemide) per 10 lb body weight (approximately 2.5 to 5 mg/kg).</p>
<p>Administered once or twice daily, permitting a 6- to 8-hour interval between treatments. In refractory or severe edematous cases, the dosage may be doubled or increased by increments of 1 mg/lb body weight as recommended in preceding paragraphs, "<span class="Bold">DOSAGE AND ADMINISTRATION</span>."</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="L00cd11ea-11d5-45bf-af31-b30cd7b75285"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED<br>Oral:</h1>
<p class="First">Furosemide Syrup 1% (10 mg/mL), available in 60 mL bottles with calibrated safety dropper.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="L2b622ac9-0a59-45de-b167-ab01605320b7"></a><a name="section-10"></a><p></p>
<h1>  TOXICOLOGY
</h1>
<p class="First"></p>
<p><span class="Bold">Acute Toxicity:</span></p>
<p>The following table illustrates low acute toxicity of Furosemide Syrup 1% in three different species. (Two values indicated two different studies).</p>
<table width="100%">
<caption><span>LD<span class="Sub">50</span> of Furosemide Syrup 1 percent in mg/kg body weight</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"> SPECIES</span></td>
<td><span class="Bold"> ORAL</span></td>
<td><span class="Bold"> INTRAVENOUS</span></td>
</tr>
<tr>
<td> Mouse</td>
<td> 1050-1500</td>
<td> 308</td>
</tr>
<tr>
<td> Rat</td>
<td> 2650-4600*</td>
<td> 680</td>
</tr>
<tr>
<td> Dog</td>
<td> &gt;1000 and &gt;4640</td>
<td> &gt;300 and &gt;464</td>
</tr>
<tr class="Last">
<td> </td>
<td> </td>
<td> </td>
</tr>
</tbody>
</table>
<p><br>*NOTE: The lower oral LD50 value for the rat was obtained in a group of fasted animals; the higher figure is from a study performed on fed rats.</p>
<p>Toxic doses lead to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and collapse. Animals surviving toxic doses may become dehydrated and depleted of electrolytes due to the massive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and saluresis.</p>
<p></p>
<p><span class="Bold">Chronic Toxicity:</span></p>
<p>Chronic toxicity studies with Furosemide Syrup 1 % were done in a one-year study in rats and dogs. In a one-year study in rats, renal tubular degeneration occurred with all doses higher than 50 mg/kg. A six-month study in dogs revealed calcification and <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> of the renal parenchyma at all doses above 10 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="L2fc5db34-c52e-4538-a662-c4298d4d1582"></a><a name="section-11"></a><p></p>
<h1>Reproductive Studies:</h1>
<p class="First">Reproductive studies were conducted in mice, rats and rabbits. Only in rabbits administered high doses (equivalent to 10 to 25 times the recommended average dose of 2 mg/kg for dogs, horses and cattle) of furosemide during the second trimester did unexplained maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and abortions occur. Furosemide Syrup 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The effects of alcohol administered to pregnant Beagles at 3 and at 3.6 gms/kg/day throughout gestation suggests that alcohol may reduce the number of offspring per litter, the birth weight per pup and increase the incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>. There have been no studies conducted in pregnant dogs administered alcohol at levels found in Furosemide Syrup 1%.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="L0a82cdb8-ba81-4b1d-8dab-46bbb64b67b1"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Timmerman RJ, Springman FR, Thomas RK: Evaluation of furosemide, a new diuretic agent. <span class="Italics">Curr Ther Res</span> 6:88-94, 1964.</li>
<li>Muschaweck R, Hajdu P: The saluretic action of 4-Chloro-N-(2 furylmethyl)-5-sulfamyl-anthranilic acid. (Die salidiuretische Wirksamkeit der Chlor-N-(2- furylmethyl)-5-sulfamyl-anthranilsaure.) <span class="Italics">Arzneim Forsch</span> 14:44-47, 1964.</li>
<li>Suki W, Rector FC Jr, Seldin DW: The site of action of furosemide and other sulfonamide diuretics in the dog. <span class="Italics">J Clin Invest</span> 44:1458-1469. 1965.</li>
<li>Deetjen P: Micropuncture studies of the action of furosemide. (Mikropunktionsuntersuchungen zur Wirkung von Furosemid.) <span class="Italics">Pfuegers Arch</span> 284: 184-190, 1965.</li>
<li>Berman LB, Ebrahimi A: Experiences with furosemide in <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. <span class="Italics">Proc Soc Exp Biol Med</span> 118:333-336, 1965.</li>
<li>Schmidt HAE: Animal experiments with S35 tagged Lasix<span class="Sup">®</span> in canine and ovine. Internal report, Radiochemical Pharmacological Laboratory, Frankfurt, West Germany, Farbwerke Hoechst, 1964.</li>
<li>Haeussler A, Hajdu P: Methods of biological identification and results of studies on absorption, elimination, and metabolism. Internal report, Research Laboratories, Frankfurt, West Germany, Farbwerke Hoechst.</li>
<li>Wilson AF, Simmons DH: Diuretic action in hypochloremic dogs. <span class="Italics">Clin Res</span> 14:158, 1966.</li>
<li>Hook JB, Williamson HE: Influence of probenecid and alterations and acid-base balance of the saluretic activity of furosemide. <span class="Italics">J Pharmacol Exp Ther</span> 149:404-408, 1965.</li>
<li>Antoniou LD, et al: Sodium and calcium transport in the kidney. <span class="Italics">Clin Res</span> 15:476, 1967.</li>
<li>Duarte CG: Effects of furosemide (F) and ethacrynic acid (ETA) on the renal clearance of phosphate (Cp), ultra-filterable calcium (CUf-Ca) and magnesium (CUfMg) <span class="Italics">Clin Res</span> 15:357, 1967.</li>
<li>Duarte CG: Effects of ethacrynic acid and furosemide on urinary calcium, phosphate and magnesium. <span class="Italics">Metabolism</span> 17:867-876, 1968.</li>
<li>Nielsen SP, Andersen O, Steven KE, Magnesium and calcium metabolism during prolonged furosemide (Lasix<span class="Sup">®</span>) administration to normal rats. <span class="Italics">Acta Pharmacol Toxicol</span> 27:469-479, 1969.</li>
<li>Reimold EW: The effect of furosemide on <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> due to dihydrotachysterol. <span class="Italics">Metabolism</span> 21 :593-598, 1972.</li>
</ol>
<p class="First"></p>
<p>Iss.01-06</p>
<p>Manufactured by: First Priority. Inc. Elgin, IL 60123-1146</p>
<p>ANADA# 200-373, Approved by FDA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L9eb5e62a-6dee-463a-bb8f-392b3f8ebe6c"></a><a name="section-13"></a><p></p>
<p class="First"><img alt="image of bottle/case label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9ca6640e-dbfb-4bcd-bf3e-c8c68b7d41a1&amp;name=LBPCOM070_i0106.jpg"></p>
<p><span class="Bold">image of bottle/case label</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L2b010746-6a09-43e2-a1f7-25cb119d14c1"></a><a name="section-14"></a><p></p>
<p class="First"><img alt="image of inner carton labeling" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9ca6640e-dbfb-4bcd-bf3e-c8c68b7d41a1&amp;name=PBXPCOM070_i1205.jpg"></p>
<p><span class="Bold">image of inner carton labeling</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FUROSEMIDE 		
					1%</strong><br><span class="contentTableReg">furosemide syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58829-303</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FUROSEMIDE</strong> (FUROSEMIDE) </td>
<td class="formItem">FUROSEMIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58829-303-60</td>
<td class="formItem">12  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANADA</td>
<td class="formItem">ANADA200373</td>
<td class="formItem">01/15/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>FIRST PRIORITY INCORPORATED
							(179925722)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">FIRST PRIORITY INCORPORATED</td>
<td class="formItem"></td>
<td class="formItem">179925722</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>34d9a7c1-d571-44c3-b104-db3fae02593d</div>
<div>Set id: 9ca6640e-dbfb-4bcd-bf3e-c8c68b7d41a1</div>
<div>Version: 3</div>
<div>Effective Time: 20130408</div>
</div>
</div> <div class="DistributorName">FIRST PRIORITY INCORPORATED</div></p>
</body></html>
